2020 American Transplant Congress
Evaluation of Cytomegalovirus Prophylaxis in Low and Intermediate Risk Kidney Transplant Recipients Receiving Lymphocyte-Depleting Induction
Hartford Hospital, Hartford, CT
*Purpose: This study evaluates if choice and duration of Cytomegalovirus (CMV) prophylaxis based on donor (D) and recipient (R) CMV serostatus impacts the incidence of…2020 American Transplant Congress
T Cell Dysfunction as Measured by Impaired Antigen Response is Associated with Infection and Frailty in Kidney Transplant Recipients
David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Kidney transplant recipients are at risk for infection, especially the growing numbers of older patients. Our previous studies demonstrated that senescent and exhausted T…2020 American Transplant Congress
Lack of Drug-Drug Interaction between Maribavir and Voriconazole
*Purpose: Maribavir is being evaluated in Phase 3 trials for the treatment of cytomegalovirus infections in transplant recipients. These patients often take numerous concomitant medications,…2020 American Transplant Congress
Incidence of Cytomegalovirus Infection in Deceased Donor Kidney Transplantation from Hepatitis-C Antibody Positive Donors to Hepatitis-C Antibody Negative Recipients: A National Registry Analysis
*Purpose: Deceased donor kidney transplantation (KT) from hepatitis C (HCV) infected donors into HCV uninfected recipients (HCV D+/R-) will be the standard of care in…2020 American Transplant Congress
Modulating ITK Signaling Facilitate Allogeneic Skin Engraftment and Clear LCMV Viruses by Regulating IRF-4, JAK STAT and Eomes Expression
*Purpose:Solid organ transplantation is a life-saving procedure to treat end-stage organ failure. However, transplantation of organs between genetically distinct individuals results in acute graft rejection…2020 American Transplant Congress
Clinical and Laboratory Characteristics of Early and Late-Onset Cytomegalovirus Infection Following Universal Prophylaxis in Kidney Transplant Recipients
University of California, San Francisco, San Francisco, CA
*Purpose: Cytomegalovirus (CMV) is the most important viral infection in organ recipients and can cause life-threatening infections, compromising long-term graft function. Most transplant centers use…2020 American Transplant Congress
Pharmacokinetics of Maribavir in Subjects with Moderate Hepatic Impairment
*Purpose: Maribavir, an investigational agent for cytomegalovirus (CMV) infection in transplant recipients, has received Breakthrough Therapy Designation. Maribavir is metabolized primarily in the liver through…2020 American Transplant Congress
Chronic Kidney Disease Alters the T Cell Response to Murine Cytomegalovirus
*Purpose: We have previously reported that patients with chronic kidney disease (CKD) accumulate memory T cells bearing markers of sustained antigen stimulation and enhanced pro-inflammatory…2020 American Transplant Congress
Early versus Delayed Initiation of CMV Prophylaxis after Liver Transplantation
Duke University Hospital, Durham, NC
*Purpose: To determine the incidence of CMV DNAemia in early (prior to post-op day 7) versus delayed prophylaxis in liver transplant recipients.*Methods: Retrospective, single-center study…2020 American Transplant Congress
Proinflammatory Cytokines Including IL-18 Correlate with Cytomegalovirus DNAemia in Solid Organ Transplant Recipients
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD
*Purpose: Human cytomegalovirus (CMV) is a common immunomodulatory virus that still causes significant morbidity and mortality in solid organ transplant (SOT) recipients despite prophylaxis. Cytokines…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 33
- Next Page »